JPY 2,541.50
-38.00 (-1.47%)
JPY · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 4151.T is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
187 interventional · 6 observational · 2 expanded access · 28 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.NCT06812104Dose-limiting toxicity (Part 1：Dose escalation)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: KK2845_1, KK2845_2, KK2845_3, KK2845_4, KK2845_5, KK2845_6, KK2845_7, KK2845_8, KK2845_alternative_1, KK2845_alternative_2 | Relapsed or Refractory AML and Other Hematologic Malignancies | 156 | 2031-11-30 | in 1,929 d | 2026-07-01 |
| Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With MogamulizumabNCT04014374observationalAssess toxicities or complications of transplant among patients who were treated with mogamulizumab, alone or in combination | — | Recruiting | — | Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL | 150 | Feb 2030 | ≤ 1,289 d | 2024-07-24 |
| A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid TumorsNCT06248411Dose-limiting toxicity (Only in Part 1a)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: KK2260, KK2260 | Advanced or Metastatic Solid Tumors | 189 | 2029-10-31 | in 1,169 d | 2026-05-27 |
| Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）NCT06926491Change from baseline in annualized height velocityOpen-label · Treatment | Phase 3 | Recruiting | Drug: KK8398 | Achondroplasia | 6 | 2029-05-31 | in 1,016 d | 2025-04-29 |
| A Study of KK2269 in Adult Participants With Solid TumorsNCT06266299Number of Subjects Experiencing Dose-limiting ToxicityNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: KK2269, Docetaxel | Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Non Small Cell Lung Cancer | 101 | Mar 2029 | ≤ 955 d | 2026-01-28 |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaNCT07192471Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).Non-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: KK2223 | T-cell NHL (PTCL or CTCL) | 72 | Mar 2029 | ≤ 955 d | 2026-07-01 |
| Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian PartnersNCT03745521observationalHeight | — | Active, not recruiting | Other: no intervention | X-Linked Hypophosphatemia | 226 | 2028-12-31 | in 865 d | 2025-09-05 |
| Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceNCT07132567observationalSafety (Special situation, adverse event, symptom, or disease occurring during treatment with Poteligeo) | — | Recruiting | Drug: Poteligeo 20mg | Mycosis Fungoides, Sezary Syndrome | 15 | Sep 2028 | ≤ 773 d | 2025-09-22 |
| Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)NCT04533581Objective response rate (ORR)Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: ME-401 | Indolent B-cell Non-Hodgkin's Lymphoma | 61 | 2028-05-31 | in 651 d | 2025-09-11 |
| A First-in-human Study of KK8123 in Adults With X-linked HypophosphatemiaNCT06525636Part 1: Number of participants with TEAEsNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: KK8123 | X-linked Hypophosphatemia | 24 | 2028-02-11 | in 541 d | 2025-11-14 |
| Study of KK3910 in Healthy Volunteers and Patients With Essential HypertensionNCT06823947Number of participants with adverse events (AEs)Randomized · Triple-masked · Treatment | Phase 1 | Recruiting | Drug: Placebo, KK3910 | Healthy Volunteers Essential Hypertension | 160 | Dec 2027 | ≤ 499 d | 2026-07-01 |
| A Phase 1/2 Study of KK2430 in Participants With Hematologic NeoplasmsNCT07629726Dose Level Toxicity (DLT)Open-label · Treatment | Phase 1/2 | Recruiting | Drug: KK2430 | Hematologic Neoplasms | 72 | Apr 2027 | ≤ 254 d | 2026-08-07 |
| A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid LeukemiaNCT07623616CR+CRh rateOpen-label · Treatment | Phase 2 | Recruiting | Drug: ziftomenib | Acute Myeloid Leukemia (AML) | 6 | Mar 2027 | ≤ 224 d | 2026-06-03 |
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationNCT06116890Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baselineRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: KHK4951, Aflibercept Injection | Neovascular Age-Related Macular Degeneration (nAMD) | 180 | 2026-08-31 | in 12 d | 2025-10-30 |
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaNCT06116916Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baselineRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: KHK4951, Aflibercept Injection | Diabetic Macular Edema (DME) | 150 | 2026-08-31 | in 12 d | 2025-10-30 |
| A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus ErythematosusNCT05411016Number of participants with adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Active, not recruiting | Drug: Placebo, KK4277 | Healthy Volunteers, Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | 157 | 2024-12-10actual | — | 2025-09-19 |
| Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic AnemiaNCT04870346observationalHematological response at 2 years after the start of romiplostim treatment in Study 531-003/531-004 | — | Active, not recruiting | — | Aplastic Anemia | 36 | 2024-08-31actual | — | 2025-09-11 |
| Mogamulizumab Q4week Dosing in Participants With R/R CTCLNCT04745234Number, percentage and severity of treatment emergent adverse eventsOpen-label · Treatment | Phase 2 | Unknown status | Drug: Mogamulizumab | Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory | 34 | May 2025 | — | 2024-04-25 |
| Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's LymphomaNCT03985189Number of participants with treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 1 | Completed | Drug: ME-401 | Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma | 14 | 2025-01-15actual | — | 2025-12-19 |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLHNCT04842032Change from Baseline (CFB) in mean serum phosphorus level at the end of the dose cycleOpen-label · Treatment | Phase 4 | Completed | Drug: KRN23 | X-linked Hypophosphatemia (XLH) | 28 | 2023-12-18actual | — | 2024-07-09 |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIONCT05357573Change from Baseline in mean serum phosphorus level at the end of the dosing cycle.Open-label · Treatment | Phase 4 | Completed | Drug: KRN23 | Tumor-Induced Osteomalacia (TIO) | 9 | 2023-11-22actual | — | 2024-07-09 |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLHNCT04842019Change from Baseline (CFB) in mean serum phosphorus level at the end of the dose cycleOpen-label · Treatment | Phase 4 | Completed | Drug: KRN23 | X-linked Hypophosphatemia (XLH) | 18 | 2023-08-17actual | — | 2024-07-09 |
| KW-3357 Study in Patients With Early Onset Severe PreeclampsiaNCT04182373Days of maintaining pregnancyRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Antithrombin gamma, physiological saline | Preeclampsia | 181 | 2023-05-17actual | — | 2023-11-15 |
| A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME StudyNCT03550443Time to onset of a ≥ 30% decrease in eGFR from baseline or ESRDRandomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for RTA 402 for diabetic kidney disease. | Drug: Bardoxolone methyl, Placebo | Diabetic Kidney Disease | 1,323 | 2022-11-30actual | — | 2023-09-26 |
| KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder CancerNCT03915405Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Termination was based on the business decision | Drug: KHK2455, Avelumab | Urothelial Carcinoma | 16 | 2022-11-15actual | — | 2024-04-25 |
| A Study of KRN125 in Patients With Multiple Myeloma and Malignant LymphomaNCT05007652Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with multiple myeloma.Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: KRN125(pegfilgrastim), PLR001(plerixafor), KRN8601(filgrastim), PLR001(plerixafor) | Multiple Myeloma and Malignant Lymphoma | 64 | 2022-10-25actual | — | 2023-02-21 |
| A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular DegenerationNCT04594681Number of participants with adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: The Sponsor judged that the objectives of this Phase 1 study were satisfied, and the study was terminated after the completion of Cohort 3 Step 3. | Drug: Placebo, KHK4951 | Healthy Volunteers, Wet Age-related Macular Degeneration | 116 | 2022-08-26actual | — | 2023-05-18 |
| Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisNCT04771780Incidence rates of all adverse events and adverse drug reactions that occurred or worsened after the initiation of KHK7791 treatment for 52 weeks.Open-label · Treatment | Phase 3 | Completed | Drug: KHK7791 | Hyperphosphatemia | 213 | 2022-06-27actual | — | 2023-08-02 |
| A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque PsoriasisNCT04614298To evaluate the proportion of subjects achieving 75% improvement from baseline in Psoriasis Area and Severity Index (PASI; PASI 75) at Week 12Randomized · Quadruple-masked · Treatment | Phase 4 | Withdrawnsponsor's stated reason: Due to the reconsideration of KHK4827's business in China, it. was decided to withdraw this clinical trial prior to enrollment of first participant. | Drug: KHK4827-Active, KHK4827-Placebo | Moderate to Severe Plaque Psoriasis | 0 | Feb 2022 | — | 2021-09-30 |
| Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.NCT05027646Area under the plasma concentration versus time curve AUC (0-t)Randomized · Open-label · Prevention | Phase 1 | Completed | Drug: Sancuso - Part 1, Sancuso - Part 2 | Healthy Volunteers | 134 | 2021-12-22actual | — | 2024-06-14 |
| Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal DialysisNCT04766385Changes in serum phosphorous levels from baseline values at 8 weeks after the start of administration.Open-label · Treatment | Phase 3 | Completed | Drug: KHK7791 | Hyperphosphatemia | 54 | 2021-12-01actual | — | 2022-01-11 |
| Study of AMG531 (Romiplostim) in Patients With Aplastic AnemiaNCT04095936Rate of achievement of complete response (CR) or partial response (PR)Open-label · Treatment | Phase 2/3 | Completed | Drug: Romiplostim | Aplastic Anemia | 24 | 2021-10-07actual | — | 2022-05-26 |
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisNCT04766398Changes in serum phosphorous levels from baseline values at 8 weeks after the start of administration.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: KHK7791, Placebo | Hyperphosphatemia | 169 | 2021-09-27actual | — | 2021-10-28 |
| Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in AsiaNCT03822507Mean percent change in intact parathyroid hormone (PTH) level from baseline in the evaluation periodRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: KHK7580, Cinacalcet Hydrochloride | Secondary Hyperparathyroidism | 404 | 2021-09-23actual | — | 2022-04-25 |
| A Study of KHK4827 in Subjects With Palmoplantar PustulosisNCT04061252Change from baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) total score at Week 16Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: KHK4827, Placebo | Palmoplantar Pustulosis | 126 | 2021-08-11actual | — | 2023-02-14 |
| Clinical Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisNCT04767581Changes in serum phosphorous levels from baseline values at 8 weeks after the start of administration.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: KHK7791, Placebo | Hyperphosphatemia | 165 | 2021-08-10actual | — | 2021-09-08 |
| Pharmacokinetic Study of KHK7580 in Healthy Adult VolunteersNCT04206657Plasma KHK7580 concentration at each time pointNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: 1mg KHK7580, 3mg KHK7580, 6mg KHK7580, 12mg KHK7580, 6mg KHK7580 for 8days | Healthy Volunteer | 42 | 2021-06-17actual | — | 2021-09-08 |
| A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaNCT04308096Number of subjects for each adverse eventsOpen-label · Treatment | Phase 3 | Completed | Drug: KRN23 | XLH | 27 | 2020-12-04actual | — | 2022-09-06 |
| Study of AMG531(Romiplostim) in Patients With Aplastic AnemiaNCT03957694Achievement of complete response (CR) or partial response (PR)Open-label · Treatment | Phase 2/3 | Completed | Drug: Romiplostim | Aplastic Anemia | 17 | 2020-11-05actual | — | 2022-05-26 |
| Study of KHK2375 in Subjects With Advanced or Recurrent Breast CancerNCT02623751Number and percentage of subjects with treatment-emergent adverse events including dose-limiting toxicities and serious adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: KHK2375, Exemestane | Breast Cancer | 15 | Oct 2020actual | — | 2022-06-21 |
| A Phase 3 Study of KHK4827 in Patients With Systemic SclerosisNCT03957681Change in modified Rodnan skin score (mRSS) from baseline at Week 24Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: KHK4827, Placebo | Moderate to Severe Systemic Sclerosis | 100 | 2020-10-16actual | — | 2025-07-11 |
| A Through QT/QTc Study of KW-6356NCT04342273Change from baseline in QTc interval [QTcF] (ΔQTcF)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: KW-6356, KW-6356, Placebo, Moxifloxacin | Parkinson's Disease | 128 | 2020-09-05actual | — | 2020-09-18 |
| KRN125 for Mobilization of Hematopoietic Stem CellsNCT03993639Achievement of >20 cells/μL positive for CD34 in peripheral blood from baseline to Day 7Open-label · Treatment | Phase 2 | Completed | Drug: Pegfilgrastim | Peripheral Blood Stem Cell Transplantation | 35 | 2020-07-21actual | — | 2021-01-22 |
| A Study of RTA 402 in Obese AdultsNCT04018339Changes from baseline in weight measured by Bioelectrical Impedance AnalysisRandomized · Single-masked · Other | Phase 1 | Completed | Drug: Bardoxolone methyl, Placebo | Obese Adult Male | 22 | 2020-05-28actual | — | 2020-06-23 |
| A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing PreparationsNCT03703570Change from baseline in the Movement disorder society-unified Parkinson's disease rating scale(MDS-UPDRS) part III scoreRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: KW-6356, Placebo | Parkinson's Disease | 502 | 2020-04-15actual | — | 2020-09-07 |
| Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major MetaboliteNCT04190654CmaxNon-randomized · Open-label · Other | Phase 1 | Completed | Drug: KW-6356 | Hepatic Impairment | 26 | 2020-03-20actual | — | 2024-04-25 |
| A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaNCT03233126Number of subjects for each adverse eventsOpen-label · Treatment | Phase 3 | Completed | Drug: KRN23 | X-linked Hypophosphatemic Rickets/Osteomalacia | 16 | 2020-02-17actual | — | 2022-09-06 |
| Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic DermatitisNCT03703102results2022-06-09Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: KHK4083, Placebo | Atopic Dermatitis | 274 | 2020-02-06actual | — | 2024-04-26 |
| KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid TumorsNCT02867007Number of Participants with Adverse Events as a Measure of Safety and TolerabilityOpen-label · Treatment | Phase 1 | Completed | Drug: KHK2455, Mogamulizumab | Solid Tumor, Cancer, Carcinoma | 36 | 2019-12-15actual | — | 2024-04-25 |
| Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic DermatitisNCT03846466Number of participants with adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study terminated for safety reasons. | Drug: KHK4323 IV/S, KHK4323 SC/S, KHK4323 IV/M, Placebo IV/S, Placebo IV/M, Placebo SC/S | Atopic Dermatitis | 5 | 2019-12-11actual | — | 2020-01-28 |
| Dose-finding Study of KHK7791 in Hyperphosphatemia PatientsNCT03864458To investigate the clinically recommended dose by comparing changes in serum phosphorus levels from baseline values at Week 6.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: KHK7791, Placebo | Hyperphosphatemia | 207 | 2019-12-10actual | — | 2024-03-07 |
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia PatientsNCT03864445Comparing changes in serum phosphorus levels between hemodialysis patients taking KHK7791 in combination with phosphate binders and those taking placebo in combination with phosphate binders.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: KHK7791, Placebp | Hyperphosphatemia | 47 | 2019-12-03actual | — | 2024-03-07 |
| A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HDNCT03831607Percentage of subjects who reduce the total number of taking phosphate binder tablets at the last assessment from baseline.Open-label · Treatment | Phase 2 | Completed | Drug: KHK7791 | Hyperphosphatemia | 67 | 2019-11-26actual | — | 2024-03-07 |
| A Drug Interaction Study of KW-6356 and Clarithromycin or RifampicinNCT04070495Geometric mean ratio of the pharmacokinetic parameter (AUC0-t) of KW-6356 in combination with or without a perpetrator drugNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: KW-6356, Clarithromycin, Rifampicin | Parkinson's Disease | 20 | 2019-11-19actual | — | 2019-11-29 |
| A Study of Single and Multiple Doses of KW-6356 in Healthy SubjectsNCT03830528Part A Number and percentage of subjects with treatment-emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: KW-6356 Low Dose, KW-6356 Middle Dose, KW-6356 High Dose, KW-6356 X Dose, KW-6356 Y Dose, Placebo | Parkinson's Disease | 48 | 2019-10-10actual | — | 2019-11-29 |
| Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356NCT04147910CmaxOpen-label · Other | Phase 1 | Completed | Drug: KW-6356 | Healthy Male Subjects | 8 | 2019-10-02actual | — | 2024-04-25 |
| A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)NCT02985983Percentage of ASAS 40 in axSpA subjectsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Brodalumab, Placebo | Axial Spondyloarthritis | 159 | 2019-09-23actual | — | 2024-07-16 |
| A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinNCT03970798Geometric mean ratio of the major pharmacokinetic parameter (AUC0-t) of the index substrates in combination with or without KW-6356Open-label · Treatment | Phase 1 | Completed | Drug: Midazolam, Caffeine, Rosuvastatin, KW-6356 | Parkinson's Disease | 50 | 2019-07-31actual | — | 2019-11-29 |
| A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy AdultsNCT04023903CmaxRandomized · Open-label · Other | Phase 1 | Completed | Drug: Bardoxolone methyl, Bardoxolone methyl | Healthy Subject | 36 | 2019-06-14actual | — | 2020-02-05 |
| A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)NCT03191526Improvement in Osame's motor disability scoreRandomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Due to not achieving the primary outcome. | Drug: KW-0761 0.3 mg/kg IV, Placebo (saline) | HTLV-1 Associated Myelopathy | 66 | 2019-06-06actual | — | 2022-04-14 |
| Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)NCT02181699Number of Participants with Adverse Events as a Measure of Safety and Tolerability.Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Failed treatment response | Drug: KHK2823 | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 39 | 2019-05-10actual | — | 2024-04-29 |
| Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary HyperparathyroidismNCT03280264results2021-05-27The Number and Percentage of Patients Who Achived a Serum Corrected Ca Concentration of Under 10.3 mg/dL for at Least 2weeks During Titration Phase.Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: KHK7580 | Parathyroid Carcinoma, Primary Hyperparathyroidism | 18 | 2019-04-09actual | — | 2021-05-27 |
| Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast CancerNCT03291886Progression Free Survival(PFS) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Entinostat, Entinostat(Placebo), Exemestane | Advanced or Recurrent Breast Cancer | 133 | 2019-04-04actual | — | 2022-06-21 |
| A Study of KHK4827 in Patients With Systemic SclerosisNCT04368403serum KHK4827 concentrationOpen-label · Treatment | Phase 1 | Completed | Drug: KHK4827 | Systemic Sclerosis | 8 | 2019-01-31actual | — | 2025-07-11 |
| Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)NCT02312687results2019-12-16Number of Participants With Adverse Events (AEs), Treatment Emergent AEs (TEAEs), Serious AEs (SAEs), and AEs Leading to Discontinuation or DeathOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: KRN23 | X-Linked Hypophosphatemia | 20 | 2018-11-30actual | — | 2024-05-06 |
| Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)NCT02163577results2019-05-22Change From Baseline in RSS Total Score Over TimeRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: burosumab | X-linked Hypophosphatemia | 52 | 2018-10-30actual | — | 2024-05-06 |
| Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative ColitisNCT02647866results2020-03-05Number of Subjects With Treatment-related Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: KHK4083, Placebo | Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Intestinal Diseases, Colonic Diseases, Autoimmune Disease, Abdominal Pain | 66 | Sep 2018actual | — | 2024-04-26 |
| Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid TumorsNCT02705105results2020-06-04Maximum Tolerated Dose (MTD)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Mogamulizumab + Nivolumab | Solid Tumor, Cancer, Carcinoma, Hepatocellular Carcinoma, HCC | 114 | 2018-08-22actual | — | 2024-04-25 |
| Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLHNCT02915705results2019-04-11Radiographic Global Impression of Change (RGI-C) Global Score at Week 40Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: burosumab · Drug: Oral Phosphate Supplement, active vitamin D | X-Linked Hypophosphatemia | 61 | 2018-02-12actual | — | 2024-08-29 |
| Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid TumorsNCT02476123Number of subjects reporting adverse eventsOpen-label · Treatment | Phase 1 | Completed | Biological: Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558) | Solid Tumor | 118 | 2018-02-07actual | — | 2019-06-11 |
| A Phase 1 Study of KHK4083 in Subjects With Atopic DermatitisNCT03096223Incidence of treatment-emergent adverse events (TEAEs) or drug-related TEAEs and their natureOpen-label · Treatment | Phase 1 | Completed | Drug: KHK4083 | Dermatitis, Atopic | 26 | 2018-02-07actual | — | 2018-03-27 |
| A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative ColitisNCT02985593Incidence of treatment-emergent adverse events (TEAEs) or drug-related TEAEs and their natureRandomized · Single-masked · Treatment | Phase 1 | Completed | Drug: KHK4083, Placebo | Healthy Men and Subjects With Ulcerative Colitis | 155 | 2017-12-26actual | — | 2023-08-30 |
| Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseNCT02610231results2019-12-13Evaluation of the Long-term Safety and Tolerability of Oral Istradefylline (20mg or 40mg/Day [mg/d])Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Istradefylline 20 mg or 40 mg | Idiopathic Parkinson's Disease | 239 | 2017-12-20actual | — | 2024-04-25 |
| Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid TumorsNCT02301130Number of subjects reporting adverse eventsRandomized · Open-label · Treatment | Phase 1 | Completed | Biological: mogamulizumab, MEDI4736 (Durvalumab), tremelimumab | Advanced Solid Tumors | 64 | 2017-12-08actual | — | 2024-04-25 |
| A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's DiseaseNCT03093519Number of Participants with Adverse EventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: KHK6640, Placebo | Alzheimer Disease | 21 | 2017-12-06actual | — | 2018-03-20 |
| A Study of KW-6356 in Subjects With Early Parkinson's DiseaseNCT02939391Change from baseline in the Movement disorder society-unified Parkinson's disease rating scale(MDS-UPDRS) partⅢ scoreRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: KW-6356, KW-6356, Placebo | Parkinson's Disease | 175 | 2017-11-22actual | — | 2018-03-20 |
| Study of Romiplostim(AMG531) in Subjects With Aplastic AnemiaNCT02773290Proportion of subjects achieving a hematological response (any of the platelet response, erythroid response, and neutrophil response) at Week 27Open-label · Treatment | Phase 2/3 | Completed | Biological: Romiplostim | Aplastic Anemia | 46 | 2017-11-14actual | — | 2024-07-16 |
| A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)NCT02029157Progression-free survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: ARQ197, Placebo | Liver Cancer | 386 | Aug 2017actual | — | 2017-10-09 |
| Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)NCT02537431results2018-09-25Percent Change From Baseline in OV/BV at Week 48Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: burosumab | X-linked Hypophosphatemia | 14 | 2017-08-30actual | — | 2024-06-18 |
| A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus SyndromeNCT02722798serum phosphorus concentration at each test time pointOpen-label · Treatment | Phase 2 | Completed | Drug: KRN23 | Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome | 14 | Jul 2017actual | — | 2022-09-06 |
| Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)NCT02304367results2020-07-30Percentage of Participants Achieving Mean Serum Phosphorus Levels Above 2.5 mg/dL at the Mid-Point of the Dose Intervals Between Baseline and Week 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Burosumab | Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS) | 17 | 2017-07-27actual | — | 2024-05-06 |
| A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's DiseaseNCT02127476Number of Participants with Adverse Events as a Measure of Safety and TolerabilityRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: KHK6640, Matching Placebo | Alzheimer's Disease | 57 | May 2017actual | — | 2024-06-17 |
| Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)NCT02750618results2018-06-19Change From Baseline at Week 40 in Serum PhosphorusOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Burosumab | X-Linked Hypophosphatemia | 13 | 2017-04-20actual | — | 2024-05-06 |
| Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLNCT01728805results2019-04-11Progression Free SurvivalRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: KW-0761 · Drug: Vorinostat | Cutaneous T-Cell Lymphoma | 372 | Mar 2017actual | — | 2024-04-25 |
| Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic RhinosinusitisNCT02772419The change from baseline in nasal polyp score at Week 12Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: benralizumab, benralizumab, Placebo | Eosinophilic Chronic Rhinosinusitis | 63 | 2017-03-27actual | — | 2018-04-23 |
| A Phase 4 Clinical Study of BrodalumabNCT04183881Incidence and types of adverse events and adverse reactionsOpen-label · Treatment | Phase 4 | Completed | Drug: Brodalumab 210mg SC | Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma | 138 | 2017-01-10actual | — | 2019-12-09 |
| Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung CancerNCT02358473results2018-11-30Number of Subjects Reporting Adverse EventsOpen-label · Treatment | Phase 1 | Completed | Biological: mogamulizumab · Drug: Docetaxel | Non-Small Cell Lung Cancer | 13 | Dec 2016actual | — | 2024-09-19 |
| Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)NCT02526160results2021-02-05Percentage of Participants Achieving Mean Serum Phosphorus Levels Above the LLN (2.5 mg/dL [0.81 mmol/L]) at the Mid-Point of the Dose Interval, as Averaged Across Dose Cycles Between Baseline and Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: burosumab · Other: Placebo | X-linked Hypophosphatemia | 134 | 2016-12-22actual | — | 2024-06-18 |
| Phase 3 Study of KHK7580NCT02549417Percentage of subjects in the evaluation period achieving a mean intact parathyroid hormone (PTH) level of ≥ 60 pg/mL and ≤ 240 pg/mLOpen-label · Treatment | Phase 3 | Completed | Drug: KHK7580 | Secondary Hyperparathyroidism | 39 | 2016-12-22actual | — | 2017-07-05 |
| Phase 3 Study of KHK7580NCT02549404Number of participants with adverse eventsOpen-label · Treatment | Phase 3 | Completed | Drug: KHK7580 | Secondary Hyperparathyroidism | 137 | 2016-12-06actual | — | 2017-07-05 |
| Phase 3 Study of KHK7580NCT02549391Percentage of subjects in the evaluation period achieving a mean intact parathyroid hormone (PTH) level of ≥ 60 pg/mL and ≤ 240 pg/mLRandomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: KHK7580, KRN1493 | Secondary Hyperparathyroidism | 634 | Nov 2016actual | — | 2017-03-24 |
| A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseNCT01968031results2020-11-20Change From Baseline in the Total Hours of Awake Time/Day Spent in the OFF State at Week 12Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Istradefylline 40 mg, Istradefylline 20 mg, Placebo | Idiopathic Parkinson's Disease | 613 | Oct 2016actual | — | 2024-04-25 |
| A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.NCT02377713Number of Participants with Adverse Events as a Measure of Safety and TolerabilityRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: KHK6640, Placebo | Alzheimer's Disease | 20 | Sep 2016actual | — | 2016-12-07 |
| A Study to Evaluate Abuse Potential of IstradefyllineNCT02609477Drug Liking VASRandomized · Quadruple-masked · Other | Phase 1 | Completed | Drug: Istradefylline, Phentermine 45 mg · Other: Placebo | Drug Abuse | 42 | Jul 2016actual | — | 2024-04-25 |
| Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease PatientsNCT02073981observationalChanging of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | — | Completed | — | Parkinson Disease | 1,021 | May 2016actual | — | 2023-08-07 |
| The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI StudyNCT02316821Safety: Number and types of adverse eventsRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: RTA 402, Placebo | Chronic Kidney Disease, Type 2 Diabetes | 216 | May 2016actual | — | 2017-10-27 |
| Study of KRN951 in Patients With Solid TumorsNCT00970411To define the maximum tolerated dose (MTD) of KRN-951 when administered orally for 21 days followed by a 7-day rest period.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: KRN951 | Solid Tumors | 12 | Apr 2016actual | — | 2017-01-05 |
| A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus ErlotinibNCT01377376Overall survivalRandomized · Double-masked · Treatment | Phase 3 | Terminated | Drug: ARQ 197 and Erlotinib, Placebo and Erlotinib | Non-small-cell Lung Cancer | — | Nov 2015actual | — | 2016-12-07 |
| KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)NCT01626664results2018-06-15Overall Response RateRandomized · Open-label · Treatment | Phase 2 | Completed | Biological: KW-0761 · Drug: Pralatrexate, gemcitabine plus oxaliplatin, DHAP | Adult T-cell Leukemia-Lymphoma | 71 | Aug 2015actual | — | 2024-04-25 |
| A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/OsteomalaciaNCT02181764Number and types of adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: KRN23 | X-linked Hypophosphatemic Rickets/Osteomalacia | 15 | Jun 2015actual | — | 2017-03-03 |
| Phase 1 Study of KHK2898 in Subjects With Advanced Solid TumorsNCT01516645Adverse Event collection and assessmentOpen-label · Treatment | Phase 1 | Terminated | Drug: KHK2898 | Solid Tumour | 14 | May 2015actual | — | 2017-03-16 |
| Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)NCT01611142Overall Response RateOpen-label · Treatment | Phase 2 | Completed | Biological: KW-0761 (mogamulizumab) | Peripheral T-Cell Lymphoma | 38 | May 2015actual | — | 2024-06-17 |
| ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung CancerNCT01580735Objective Response RateOpen-label · Treatment | Phase 2 | Completed | Drug: ARQ 197 | Non-small-cell Lung Cancer | 40 | Apr 2015actual | — | 2015-08-18 |
| A Phase 3 Clinical Study of KHK4827NCT01782924Incidence and types of adverse events and adverse reactionsRandomized · Treatment | Phase 3 | Completed | Drug: KHK4827 | Psoriasis | 145 | Feb 2015actual | — | 2015-02-16 |
| Phase 2 Study of KHK7580NCT02216656The percent changes in intact Parathyroid hormone levels from baselineRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, KHK7580 low dose, KHK7580 middle dose, KHK7580 high dose, KRN1493 | Secondary Hyperparathyroidism | 201 | Feb 2015actual | — | 2018-07-10 |
| Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid TumorsNCT01447732Adverse Event collection and assessment will be done for all 74 potentially treated subjects.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CEP-37250/KHK2804 | Solid Tumour, Adenocarcinoma of the Colorectal, Adenocarcinoma of the Pancreas | 71 | Jan 2015actual | — | 2024-04-29 |
| A Phase 3 Clinical Study of KHK 4827NCT02052609Incidence and types of adverse events and adverse reactionsNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: KHK4827 140mg SC, KHK4827 210mg SC | Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma | 155 | 2015-01-28actual | — | 2023-08-25 |
| An Open-label, Non-controlled Study of KHK4827 in Subjects With PsoriasisNCT01782937Clinical Global Impression (CGI)Open-label · Treatment | Phase 3 | Completed | Drug: KHK4827 | Psoriasis | 30 | Dec 2014actual | — | 2015-02-16 |
| Phase 2 Study of KHK4577NCT02004119Percent improvement from baseline in Eczema Area and Severity Index (EASI)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: KHK4577, Placebo | Atopic Dermatitis | 93 | Dec 2014actual | — | 2018-09-11 |
| Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal DialysisNCT02143271Number and types of adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: KHK7580 | Secondary Hyperparathyroidism | 13 | Dec 2014actual | — | 2015-03-05 |
| Effect of Mild Hepatic Impairment on the Pharmacokinetics of IstradefyllineNCT02256033Comparison of pharmacokinetic parameter istradefylline (Area under the concentration-time curve [AUC]) between subjects with hepatic impairment and healthy subjects with normal hepatic function using an analysis of variance modelOpen-label · Basic science | Phase 1 | Completed | Drug: Istradefylline | Hepatic Impairment | 20 | Dec 2014actual | — | 2024-04-25 |
| The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.NCT02174250Area under the concentration-time curve from time zero to infinity (AUC0 ∞) and Observed maximum plasma concentration (Cmax) of istradefyllineNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Istradefylline 40 mg, Rifampin 300mg BID + istradefylline 40mg Day 8 only | Parkinson's Disease | 20 | Aug 2014actual | — | 2024-04-25 |
| Study of ARQ 197 in Hepatocellular Carcinoma (HCC)NCT01656265Number of participants with dose-limiting toxicity (DLT), as a measure of safety and tolerabilityOpen-label · Treatment | Phase 1 | Completed | Drug: ARQ 197 | Advanced Hepatocellular Carcinoma | 24 | Mar 2014actual | — | 2017-03-03 |
| Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving HemodialysisNCT01935856The safety of KHK7580 assessed by number and types of adverse events, laboratory tests, vital signs, electrocardiogram and ophthalmic examinationOpen-label · Treatment | Phase 1/2 | Completed | Drug: KHK7580 | Hyperparathyroidism | 20 | Mar 2014actual | — | 2017-03-03 |
| A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic SyndromeNCT01497145The proportion of subjects achieving a erythroid responseRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: KRN321 | MDS | 45 | Feb 2014actual | — | 2015-03-04 |
| A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple MyelomaNCT01063907results2014-11-05To Establish the Safety, Tolerability, and RP2D (Phase 1); To Assess the Overall Response Rate in Subjects With Advanced Multiple Myeloma (Phase 2).Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: KW-2478, Bortezomib | Multiple Myeloma | 95 | Nov 2013actual | — | 2024-04-25 |
| A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes MellitusNCT01572610Efficacy: glomerular filtration rate measured by inulin clearanceOpen-label · Treatment | Phase 2 | Terminated | Drug: RTA 402 | Chronic Kidney Disease, Type 2 Diabetes | 11 | Nov 2013actual | — | 2017-03-03 |
| A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes MellitusNCT01574365Efficacy:Changes in eGFRRandomized · Open-label · Treatment | Phase 2 | Terminated | Drug: RTA 402 | Chronic Kidney Disease, Type 2 Diabetes | 53 | Nov 2013actual | — | 2017-03-03 |
| An Extension Study of KRN23 in Adults With X-Linked HypophosphatemiaNCT01571596results2021-02-17Safety and Efficacy of Repeated SC Injections of KRN23.Open-label · Treatment | Phase 1/2 | Completed | Drug: KRN23 | X-linked Hypophosphatemia | 23 | Sep 2013actual | — | 2024-06-18 |
| A Phase 2 Clinical Study of KHK4827NCT01748539Percent improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: KHK4827, Placebo | Moderate to Severe Plaque Psoriasis | 140 | Sep 2013actual | — | 2013-09-05 |
| A Phase IIa Study of KHK4563NCT01412736evaluation of the effect of multiple-dose subcutaneous(SC) administration of benralizumab on the annual asthma exacerbation rate in adult subjects with uncontrolled, suspected eosinophilic asthma.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: KHK4563, KHK4563, KHK4563, Placebo | Uncontrolled and Suspected Eosinophilic Asthma | 106 | Jul 2013actual | — | 2014-12-23 |
| A Comparative Study of KHK6188NCT01544296Change of pain intensity scoreRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: KHK6188, Placebo | Postherpetic Neuralgia | 42 | Jun 2013actual | — | 2013-10-10 |
| A Repeated Study of KRN23 in Adults With X-Linked HypophosphatemiaNCT01340482results2020-10-26Safety and Efficacy of Repeated SC Injections of KRN23Open-label · Treatment | Phase 1/2 | Completed | Drug: KRN23 | X-linked Hypophosphatemia | 29 | May 2013actual | — | 2024-06-18 |
| An Open-label Study of KW-3357NCT01384903DIC resolutionRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: KW-3357, Plasma-derived antithrombin | Disseminated Intravascular Coagulation (DIC) | 221 | May 2013actual | — | 2017-03-24 |
| A Clinical Study of KW-3357 in Patients With DICNCT01384396SafetyOpen-label · Treatment | Phase 3 | Completed | Drug: KW-3357 | Disseminated Intravascular Coagulation (DIC) | 15 | Apr 2013actual | — | 2017-03-24 |
| An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary HyperparathyroidismNCT01460030Corrected serum calciumTreatment | Phase 3 | Completed | Drug: Cinacalcet HCl | Parathyroid Carcinoma, Hypercalcemia, Primary Hyperparathyroidism | — | Feb 2013actual | — | 2017-03-03 |
| A Study of LY2523355 in Patients With Solid CancerNCT01358019Dose limiting toxicity based on the Common Terminology Criteria for Adverse Events v4.0Open-label · Treatment | Phase 1 | Completed | Drug: LY2523355 | Solid Tumors | 18 | Jan 2013actual | — | 2013-01-28 |
| Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast CancerNCT01199367To establish the safety, tolerability, and recommended Phase 2 dose of KW-2450 administered in combination with lapatinib and letrozole in subjects with previously treated or untreated advanced breast cancer.Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The results of the dose escalation phase did not identify a well-tolerated dose that would permit further study in Phase 2. | Drug: KW-2450 in combination with lapatinib and letrozole | Breast Cancer | 11 | Dec 2012actual | — | 2024-04-25 |
| A Study of ARQ 197 in Combination With ErlotinibNCT01251796Dose-Limiting Toxicity in the combination of tivantinib and erlotinibTreatment | Phase 1 | Completed | Drug: ARQ 197 and Erlotinib | Advanced/Recurrent Non-small-cell Lung Cancer | 9 | Nov 2012actual | — | 2017-03-15 |
| Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian CancerNCT01279291Number of Participants with Adverse Events as a Measure of Safety and TolerabilityNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was stopped due to the inability to determine an acceptable dose with the potential for further study | Biological: KHK2866 · Drug: Gemcitabine and Carboplatin, paclitaxel, pegylated liposomal doxorubicin | Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasm | 22 | Nov 2012actual | — | 2024-04-26 |
| A Phase 3 Clinical Study of KW-3357 in Patients With DICNCT01384409SafetyOpen-label · Treatment | Phase 3 | Terminated | Drug: KW-3357 | Disseminated Intravascular Coagulation (DIC) | 5 | Oct 2012actual | — | 2017-03-24 |
| Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell LymphomaNCT00888927results2020-12-29Maximum Tolerated DoseNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: KW-0761 | Peripheral T-Cell Lymphoma | 42 | Sep 2012actual | — | 2024-04-25 |
| Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001NCT01226472results2020-12-29Global Composite Response (Skin, Blood, Lymph Nodes)as Determined by Skin Evaluations, Blood Counts and PET/CT ImagingOpen-label · Treatment | Phase 2 | Completed | Biological: KW-0761 | Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma | 1 | Sep 2012actual | — | 2024-04-25 |
| A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe PsoriasisNCT01488201SafetyRandomized · Single-masked · Treatment | Phase 1 | Completed | Drug: Placebo, KHK4827 | Psoriasis | 48 | Sep 2012actual | — | 2012-11-02 |
| Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal CancerNCT00838578results2015-03-23Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Per protocol, the study was terminated based on interim analysis results | Biological: KRN330 · Drug: Irinotecan | Colorectal Cancer | 65 | Jul 2012actual | — | 2024-04-26 |
| A Comparative Study of KW-2246NCT01326689Pain intensity differenceRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: KW-2246, Placebo | Cancer Related Pain (Breakthrough Pain) | 42 | Jun 2012actual | — | 2017-03-08 |
| Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell LymphomaNCT01192984Antitumor effect (best overall response)Treatment | Phase 2 | Completed | Biological: KW-0761 | Peripheral T/NK-cell Lymphoma | 38 | May 2012actual | — | 2017-03-03 |
| Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15NCT01173887Complete response rate in the best overall response assessment for antitumor effectRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: VCAP/AMP/VECP(mLSG15) · Biological: KW-0761 | Adult T-cell Leukemia-Lymphoma | 44 | Apr 2012actual | — | 2017-03-30 |
| A Phase 3 Study of OPC-262 in Patients With Type 2 DiabetesNCT01193179Adverse events, clinical laboratory testsOpen-label · Treatment | Phase 3 | Completed | Drug: OPC-262 | Diabetes, Type 2 | 450 | Apr 2012actual | — | 2014-01-08 |
| A Study of KRN23 in X-linked HypophosphatemiaNCT00830674Safety and tolerabilityRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Placebo, KRN23 | X-linked Hypophosphatemia | 42 | Dec 2011actual | — | 2024-06-17 |
| A Phase 1 Study of ARQ 197 in Patients With Solid TumorsNCT00609921Determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197Open-label · Treatment | Phase 1 | Completed | Drug: ARQ197 | Cancer | 42 | Sep 2011actual | — | 2012-09-07 |
| Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease PatientsNCT00957203Adverse eventsOpen-label · Treatment | Phase 3 | Completed | Drug: Istradefylline | Parkinson's Disease | 308 | Sep 2011actual | — | 2012-08-31 |
| A Study of ARQ 197 in Combination With ErlotinibNCT01069757Dose-Limiting Toxicity in the combination of tivantinib and erlotinibOpen-label · Treatment | Phase 1 | Completed | Drug: ARQ 197 and Erlotinib | Non-small-cell Lung Cancer | 16 | Sep 2011actual | — | 2017-03-15 |
| Extended Long-Term Safety Study of KW-6500NCT01063621Adverse events and related adverse eventsOpen-label · Treatment | Phase 3 | Completed | Drug: KW-6500 | Parkinson's Disease | 27 | Aug 2011actual | — | 2017-03-15 |
| Study of ARQ 197 MonotherapyNCT01152645Antitumor effectOpen-label · Treatment | Phase 2 | Completed | Drug: ARQ 197 | Gastric Cancer | 31 | Aug 2011actual | — | 2017-03-15 |
| Open Label Extension Study of AMG 531 in Japanese Subjects With ITPNCT00440037results2020-01-21Percentage of Participants With Adverse Events Including Clinically Significant Changes in Laboratory Values.Open-label · Treatment | Phase 2/3 | Completed | Biological: AMG 531 | Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | 44 | Jul 2011actual | — | 2020-01-21 |
| A Study of OPC-262 in Patients With Type 2 DiabetesNCT01046318Changes in HbA1C from baseline to each visit (OC) and Week 52 (LOCF)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: OPC-262 | Type 2 Diabetes | 100 | Jul 2011actual | — | 2014-01-08 |
| Along-term Study of OPC-262 in Patients With Type 2 DiabetesNCT01634282Change in HBA1c form baselineOpen-label · Treatment | Phase 3 | Completed | Drug: OPC-262 | Diabetes, Type 2 | 222 | Jun 2011actual | — | 2014-01-08 |
| Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple MyelomaNCT00775502Serum M protein levelsOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: lack of efficacy in Multiple myeloma | Drug: BIW-8962 | Multiple Myeloma | 23 | May 2011actual | — | 2024-04-25 |
| Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking LevodopaNCT00955526Reducing the mean total hours of awake time per day spent in the OFF stateRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Istradefylline, Istradefylline, Placebo | Parkinson's Disease | 373 | Feb 2011actual | — | 2012-08-29 |
| Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney DiseaseNCT00995163observationalall-cause mortality | — | Completed | — | End Stage Renal Disease, Hyperparathyroidism, Secondary | 8,020 | Jan 2011actual | — | 2012-08-23 |
| Long-Term Safety Study of KW-6500 in Patients With Parkinson's DiseaseNCT00955318The incidence of adverse events after administration of KW-6500Open-label · Treatment | Phase 3 | Completed | Drug: KW-6500 | Parkinson's Disease | 58 | Dec 2010actual | — | 2017-03-15 |
| A Study of KW-3357 in Congenital Antithrombin DeficiencyNCT00938288To evaluate the pharmacokinetic profile of a single dose (50 IU/kg) of KW 3357 in subjects with congenital AT deficiencyOpen-label · Other | Phase 1 | Completed | Drug: KW-3357 | Congenital Antithrombin Deficiency | 16 | 2010-12-22actual | — | 2024-10-17 |
| A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes MellitusNCT01162876PharmacokineticsOpen-label · Other | Phase 3 | Completed | Drug: saxaglipitin | Diabetes | 20 | Nov 2010actual | — | 2017-03-09 |
| A Study of OPC-262 in Patients With Type 2 DiabetesNCT00997282Changes in HbA1C from baselineRandomized · Quadruple-masked · Treatment | Phase 2/3 | Completed | Drug: OPC-262 2.5 mg, OPC-262 5 mg, Placebo | Diabetes Type 2 | 255 | Oct 2010actual | — | 2014-01-08 |
| Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500NCT01058291The raw score change in UPDRS part III scoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: KW-6500, KW-6500 Placebo | Parkinson's Disease | 31 | Oct 2010actual | — | 2017-03-03 |
| A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaNCT00457782To determine Safety & Tolerability by adverse event rates in order to determine recommended Phase II doseOpen-label · Treatment | Phase 1 | Completed | Drug: KW-2478 | Multiple Myeloma, Chronic Lymphocytic Leukaemia, B-cell Non-Hodgkin's Lymphoma | 27 | Aug 2010actual | — | 2024-04-25 |
| Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid TumorNCT00921336To establish the safety, tolerability, and recommended Phase 2 dose of KW 2450 administered orally in subjects with advanced solid tumor who have not responded to standard therapy or for whom no standard therapy is availableOpen-label · Treatment | Phase 1 | Completed | Drug: KW-2450 | Solid Tumor | 13 | Aug 2010actual | — | 2024-04-25 |
| Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphomaNCT00920790results2012-09-25Overall Response Rate (ORR)Open-label · Treatment | Phase 2 | Completed | Biological: KW-0761 | Adult T-cell Leukemia-lymphoma | 28 | Jul 2010actual | — | 2017-03-29 |
| Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)NCT00779480Safety as determine by adverse event rate and dose limiting toxicityOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Failure to demonstrate a tolerable dose that had potential for efficacy. | Drug: KW-2449 | Acute Myelogenous Leukemia (AML) | 14 | Apr 2010actual | — | 2024-04-25 |
| Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy SubjectsNCT01073696Pharmacokinetic profile of the granisetron patch in healthy subjects when heat is appliedNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: granisetron IV, granisetron patch | Healthy | 16 | Apr 2010actual | — | 2024-06-17 |
| A Phase 2 Study of OPC-262 in Patients With Type 2 DiabetesNCT00857558changes in HbA1C from baselineRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: saxagliptin, saxagliptin, saxagliptin, placebo | Diabetes, Type 2 | 350 | Mar 2010actual | — | 2017-03-09 |
| Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal CancerNCT00575562The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: KRN330 | Colorectal Cancer | 42 | Jan 2010actual | — | 2024-04-29 |
| An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal GranisetronNCT00868764Pharmacokinetic profile of the granisetron patch in elderly subjects (Part 1) and in underweight and obese subjects (Part 2)Open-label · Other | Phase 1 | Completed | Drug: granisetron | Pharmacokinetics | 60 | Sep 2009actual | — | 2024-07-24 |
| Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)NCT00890565Time-matched, placebo-corrected change from baseline in QTc based on the Fridericia correction (QTcF).Randomized · Single-masked · Other | Phase 1 | Completed | Drug: granisetron | Healthy | 240 | Aug 2009actual | — | 2024-06-17 |
| A Phase III Clinical Study of KW-2246NCT00683995Open-label · Treatment | Phase 3 | Completed | Drug: KW-2246 (fentanyl citrate) | Pain, Cancer | 43 | Jul 2009actual | — | 2020-08-28 |
| PK, Tolerability and Safety of the Co-administration of Sancuso® (Transdermal Granisetron) and IV GranisetronNCT00873197Pharmacokinetic profile of the co-administration of IV granisetron and the Sancuso® patchOpen-label · Other | Phase 1 | Completed | Drug: granisetron | Healthy | 12 | May 2009actual | — | 2024-06-17 |
| A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer PatientsNCT00684632Randomized · Quadruple-masked · Supportive care | Phase 3 | Completed | Drug: Placebo, KW-2246 (fentanyl citrate) | Pain, Cancer | 51 | Apr 2009actual | — | 2020-08-28 |
| Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.NCT00262678Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: EN3267 | Pain, Cancer | — | Dec 2008actual | — | 2009-06-04 |
| Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer PatientsNCT00263575results2020-11-19Evaluate the Long-term Safety and Effectiveness of EN3267Open-label · Treatment | Phase 3 | Completed | Drug: EN3267 | Pain, Cancer | 139 | Dec 2008actual | — | 2024-06-18 |
| An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001NCT00199381results2013-07-30Safety as Measured by Adverse EventsOpen-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Additional long-term safety data no longer needed | Drug: Istradefylline | Parkinson's Disease | 504 | Oct 2008actual | — | 2024-05-17 |
| Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCLNCT00355472results2012-09-07Incidence of Dose-Limiting Toxicities (DLTs)Open-label · Treatment | Phase 1 | Completed | Drug: KW-0761 | Adult T-Cell Leukemia and Lymphoma (ATL), Adult Peripheral T-Cell Lymphoma (PTCL) | 16 | Oct 2008actual | — | 2012-10-18 |
| Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa TherapyNCT00610103The change (response ratio, raw score change, percent score change) in UPDRS (Unified Parkinson's Disease Rating Scale ) Part 3 score at the maintenance dose levelRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: apomorphine hydrochloride | Parkinson's Disease | 16 | Oct 2008actual | — | 2020-08-28 |
| A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaNCT00455507To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with Parkinson's disease (PD) treated with levodopa/dopa-decarboxylase inhibitor.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Istradefylline, Istradefylline, Placebo | Parkinson's Disease | 363 | Aug 2008actual | — | 2012-08-29 |
| An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous LeukemiaNCT00346632results2016-08-12Safety of KW-2449 - Number of Participants With Treatment-related Adverse Events (TEAEs) as Assessed by NCI-CTCAE v3.0Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Terminated due to suboptimal dosing schedule | Drug: KW-2449 | Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia | 37 | Apr 2008actual | — | 2024-05-17 |
| Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic PatientsNCT00364468To compare the duration of severe neutropeniaRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: pegfilgrastim | Neutropenia | 107 | Mar 2008actual | — | 2017-03-03 |
| A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid TumorNCT00359840To compare the effectiveness of KRN321(darbepoetin alfa) on the proportion of subjects achieving hemoglobin responseRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: darbepoetin alfa | Anemia | 120 | Sep 2007actual | — | 2012-08-31 |
| Clinical Study of KW-2246 in Patients With Cancer PainNCT00355628Safety and TolerabilityOpen-label · Treatment | Phase 2 | Completed | Drug: KW-2246 (fentanyl citrate) | Pain, Cancer | 40 | Jul 2007actual | — | 2012-08-31 |
| A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer PatientsNCT00344409To compare the proportion of subjects who reach red blood cell transfusion triggerRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: darbepoetin alfa | Anemia | 200 | May 2007actual | — | 2012-08-31 |
| An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018NCT00199368SafetyNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Istradefylline ( KW-6002) | Parkinson's Disease | 1,100 | Mar 2007actual | — | 2024-04-25 |
| Safety Study of AMG 531 in Japanese Subjects With ITPNCT00305435Incidence of all adverse events including evaluation of antibody statusOpen-label · Treatment | Phase 2 | Completed | Drug: Romiplostim (AMG-531) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | 12 | Nov 2006actual | — | 2024-07-05 |
| A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseaseNCT00250393To establish the efficacy of 40mg/d doses of istradefylline for the change in UPDRS part-III (Motor examination) score in patients with Parkinson's disease (PD).Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease | 64 | Oct 2006actual | — | 2012-08-29 |
| Study of Istradefylline (KW-6002) for the Treatment of Restless Legs SyndromeNCT00199446Change from baseline in an RLS rating scale score at endpoint (6 weeks of treatment or early discontinuation).Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Istradefylline (KW-6002) | Sleep Disorder, Restless Legs Syndrome | 160 | Aug 2006actual | — | 2024-04-25 |
| A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) PatientsNCT00199433Change from baseline in the UPDRS subscale III at endpoint.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease, Movement Disorder Syndrome | 160 | Jul 2006actual | — | 2024-04-25 |
| A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaNCT00199355To establish the efficacy of 20 mg/d and 40mg/d doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/DCI.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease | 75 | Mar 2006actual | — | 2014-05-23 |
| A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaNCT00199407To establish the efficacy of a 20 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease | 230 | Nov 2005actual | — | 2024-04-25 |
| A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on LevodopaNCT00199420To establish the efficacy of 10, 20 and 40 mg/d istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease | 580 | Nov 2005actual | — | 2024-04-25 |
| A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced MelanomaNCT00199342To determine the MTD and a recommended Phase II dose of KW-2871 administered with a specified premedication regimen (rantidine, diphenhydramine, and dexamethasone) in patients with Stage IV melanoma.Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Occurrence of 2 dose-limiting toxicities at the initial dose level (60 mg/m2) in Part I. | Drug: KW-2871 | Stage IV Melanoma | 5 | Oct 2005actual | — | 2024-05-03 |
| A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseaseNCT00199394OFF time assessed by patient diaries at endpoint.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease | 405 | Oct 2005actual | — | 2024-04-25 |
| 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/CarbodopaNCT00456794Change from Baseline to Endpoint in percentage of awake time per day in an OFF state based on the subjects' valid ON/OFF Parkinson's disease diary data.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease | 325 | Oct 2003actual | — | 2024-04-25 |
| A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa TherapyNCT00955045 | Phase 2/3 | Completed | Drug: istradefylline | Parkinson's Disease | — | Oct 2003actual | — | 2024-04-25 |
| 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/CarbidopaNCT00456586To evaluate the safety and efficacy of 40 mg/day istradefylline for reducing OFF time in subjects with Parkinson's disease (PD) treated with levodopa/carbidopa.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: KW-6002 (istradefylline) | Parkinson's Disease | 180 | May 2003actual | — | 2024-04-25 |
| To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)NCT00273468Percentage of patients achieving Complete Control of CINV from the first administration until 24 h after the last administration of the moderately or highly emetogenic chemotherapyRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Granisetron | Chemotherapy-induced Nausea and Vomiting | 630 | — | — | 2024-06-17 |
| Expanded Access to BurosumabNCT03775187expanded access | — | Available | Biological: Burosumab | X-linked Hypophosphatemia, Tumor-Induced Osteomalacia | — | — | — | 2025-03-05 |
| Expanded Access for KHK2455NCT04321694expanded access | — | No longer available | Drug: KHK2455 | Glioblastoma Multiforme | — | — | — | 2024-04-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19